For BPC-157 specifically, the FDA reported limited and short human studies, a lack of adequate studies for several commonly used routes of administration, potential immunogenicity concerns, possible liver and clotting signals in animal studies, and three adverse-event reports, while noting that a cause could not be established
Now that scientists know how to manipulate the internal cellular switch using enzyme inhibitors to sustain the brains response, it opens up the real possibility of extending the drugs lifetime in the body, potentially reducing how often these medications need to be administered
[1] [3] Administered as a once-weekly subcutaneous injection, it works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in response to elevated blood glucose levels, suppresses glucagon release, and slows gastric emptying
The smartest inner beauty routine is not the one with the most dramatic promise
Injectable options remain significantly more effective